Publications by authors named "R Gressin"
Background: MYC-driven lymphomas are a subset of B-cell lymphomas characterized by genetic alterations that dysregulate the expression of the MYC oncogene. When overexpressed, typically through chromosomal translocations, amplifications, or other mechanisms, MYC can drive uncontrolled cell growth and contribute to cancer development. MYC-driven lymphomas are described as aggressive entities which require intensive treatment approaches and can be associated with poor prognosis.
View Article and Find Full Text PDFArticle Synopsis
- Vitreoretinal lymphoma (VRL) has a poor prognosis due to high relapse rates in the central nervous system, requiring treatments like high-dose chemotherapy with autologous stem cell transplantation (HCT-ASCT).
- A study analyzed 38 adult patients treated with HCT-ASCT for isolated VRL over 11 years, showing that 84% received a thiotepa-based regimen, with some patients experiencing serious side effects.
- Results revealed a significant relapse rate, particularly in the brain, but the strategy showed relatively good median survival rates: 96 months for progression-free survival and 92 months overall.
Marginal Zone Lymphoma (MZL) comprises three subtypes: extranodal MZL (EMZL), splenic MZL (SMZL) and nodal MZL (NMZL). Since clinical trials have limited representativeness, there is a need for real-world data (RWD) evidence in MZL. Real-world data in Lymphoma and survival in Adults (REALYSA) is a prospective multicentric French cohort of newly diagnosed lymphoma patients.
View Article and Find Full Text PDFArticle Synopsis
- Follicular helper T-cell lymphomas (TFHL) often have gene alterations affecting DNA methylation, and preliminary studies indicate that 5-azacitidine may be effective for patients with relapsed TFHL.
- This study compared the oral azacitidine treatment to typical therapies (like gemcitabine and bendamustine) in patients over 18 with relapsed or refractory TFHL across five European countries and Japan.
- The trial enrolled 86 patients, showing that those treated with azacitidine had a median progression-free survival of 5.6 months, significantly longer compared to 2.8 months for those receiving standard therapy.
Article Synopsis
- - Obinutuzumab (O) and rituximab (R) were compared in a long-term study (LyMa-101) for treating newly diagnosed mantle cell lymphoma (MCL) patients, focusing on outcomes like measurable residual disease (MRD), progression-free survival (PFS), and overall survival (OS).
- - Results showed that the O group had a higher rate of MRD negativity (83.1% vs 63.4%) and better long-term outcomes, with 5-year PFS at 82.8% and OS at 86.4%, compared to 66.6% and 71.4% for the R group, respectively.
- - The study concluded that using